Ocugen to Host Conference Call on Friday, November 8 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Hig...
October 25 2019 - 6:30AM
Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical
company focused on discovering, developing and commercializing a
pipeline of innovative therapies that address rare and underserved
eye diseases, today announced that it will release corporate and
financial results for the third quarter that ended September 30,
2019 before the open of the U.S. financial markets on Friday,
November 8, 2019. The company will host a conference call at
8:30 a.m. ET on the same day to discuss the results and recent
business highlights.
The call can be accessed by dialing (844) 987-9316 (domestic) or
(602) 563-8454 (international) and providing the conference ID
9979278. To access a live audio webcast of the call on the
“Investors” section of the Ocugen website, please click here.
A replay of the webcast will be archived on Ocugen’s website for
approximately 45 days following the call.
About Ocugen, Inc. Ocugen, Inc. is a clinical
stage biopharmaceutical company focused on discovering, developing
and commercializing a pipeline of innovative therapies that address
rare and underserved eye diseases. The Company offers a robust and
diversified ophthalmology portfolio that includes novel gene
therapies, biologics, and small molecules and targets a broad range
of high-need retinal and ocular surface diseases. Ocugen is
leveraging its groundbreaking modifier gene therapy platform to
address genetically diverse inherited retinal diseases (IRDs) and
dry AMD, based on nuclear hormone receptor genes NR2E3 (OCU400) and
RORA (OCU410), respectively. OCU400 has received two orphan
drug designations (ODD) targeting two distinct IRDs. Ocugen
is also developing novel biologic therapies for wet-AMD, DME and
diabetic retinopathy (OCU200), as well as for retinitis pigmentosa
(OCU100). The Company’s late-stage Phase 3 trial for patients
with ocular graft versus host disease (oGVHD)(OCU300) leverages
Ocugen’s patented OcuNanoE – Ocugen’s ONE Platform™ technology to
enhance the efficacy of topical ophthalmic therapeutics. OCU300 is
the first and only therapeutic with ODD for oGVHD, providing
certain regulatory and economic benefits. For more information,
please visit www.ocugen.com.
Corporate Contact:
Ocugen, Inc.
Kelly Beck
kelly.beck@ocugen.com
+1 484-328-4698
Media Contact:
LaVoieHealthScience
Emmie Twombly
etwombly@lavoiehealthscience.com
+1 857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024